FRI0026 U-act-early trial 3 years follow-up. the longer effectiveness of treat-to-target strategies in early ra with tocilizumab, methotrexate, or their combination

Abstract

BackgroundThe U-Act-Early trial was a 2 year placebo controlled, double-blind randomised controlled trial in early (DMARD-naïve) RA patients treated to the target of sustained remission (SR), starting with tocilizumab (TCZ),...